Key facts
- This page summarizes Tomas Kiselak's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 16 Jun 2021, 18:34.
Tomas Kiselak - 03 Jun 2021 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)
- Role
- Director
- Signature
- /s/ Lara Meisner, Attorney-in-Fact for Tomas Kiselak
- Issuer symbol
- VRDN
- Transactions as of
- 03 Jun 2021
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 16 Jun 2021, 18:34:47 UTC
- Next filing
- 10 Jun 2022
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Tomas Kiselak filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 16 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
VRDN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 03 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $16.60
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option vests in full upon the earlier to occur of (i) June 3, 2022 or (ii) the Issuer's 2022 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. |